Estradiol

(redirected from Climara)
Also found in: Dictionary, Thesaurus, Medical.

estradiol

[‚es·trə′dī‚ȯl]
(biochemistry)
C18H24O2 An estrogenic hormone produced by follicle cells of the vertebrate ovary; provokes estrus and proliferation of the human endometrium, and stimulates ICSH (interstitial-cell-stimulating hormone) secretion.

Estradiol

 

C18H24O2, a female sex hormone of the estrogen group with the structural formula

Estradiol occurs as colorless crystals with a melting point of 176°–178°C. Poorly soluble in water, it dissolves better in organic solvents. It is optically active, with a specific rotation of [α]D= +81°.

Estradiol was first isolated in 1935 from the follicular fluid of the ovaries of swine by the American biochemist E. Doisy. Of all the estrogens, it has the highest physiological activity, but it is rapidly inactivated in the body. Longer-acting preparations of estradiol (estradiol dipropionate and estradiol benzoate) are obtained by the esterization of estradiol with various organic acids. Estradiol has important physiological functions (seeESTROGEN).

References in periodicals archive ?
I would suggest that you might want to try another patch, since the Climara did not work for you, and see if that is better for you.
Two randomized, controlled clinical trials showed that Climara Pro significantly reduced the frequency and severity of hot flashes as early as 1 week into therapy, and that 90% of women experienced an 80% reduction in hot flashes by week 12, according to Berlex Inc.
While it has long been accepted that estrogen helps maintain bone density following menopause, our studies, and this new indication, solidify the positive effect that Climara Pro has on bones, while helping women manage moderate to severe vasomotor symptoms associated with menopause," said Paul Korner, M.
Berlex currently markets the low dose, once weekly, transdermal hormone therapies, Climara(R) (estradiol transdermal system) and Climara Pro(R) (estradiol and levonorgestrel transdermal system).
Climara is indicated for the treatment of vasomotor menopausal symptoms, vulval and vaginal atrophy, hypoestrogenism, and the prevention of osteoporosis.
With the FDA-approved Climara Pro patch, women now have an effective, once-a-week option that provides rapid relief of vasomotor symptoms associated with menopause with the lowest available estrogen dose in combination therapy.
Food and Drug Administration (FDA) has granted marketing approval for Climara Pro(R) (estradiol/levonorgestrel) transdermal system.
Food and Drug Administration (FDA) has granted marketing approval for Climara Pro(R) (estradiol/levonorgestrel transdermal system) for the treatment of menopausal symptoms.
With the addition of two new doses, the Climara product line now offers the broadest dosing range available of any transdermal hormone therapy product.